IPSEN, OOO

🇷🇺Russia

Country: 🇷🇺Russia

Ownership: -

Established: 1929-01-01

Employees: 5.7K

Market Cap: $9.8B

Website: https://www.ipsen.com/

Clinical Trials

Study of Cabozantinib as 2nd Line Treatment in Subjects With Locally Advanced or Metastatic Renal Cell Carcinoma (RCC) With a Clear-Cell Component Who Progressed After 1st Line Treatment With Checkpoint Inhibitors

Phase 2

Active, not recruiting

Conditions: Locally Advanced or Metastatic Renal Cell Carcinoma

Interventions: Drug: Cabozantinib

First Posted Date: 2019-05-10

Last Posted Date: 2024-12-19

Lead Sponsor: Ipsen

Target Recruit Count: 127

Registration Number: NCT03945773

Locations: 🇳🇱
Maxima Medisch Centrum, Eindhoven, Netherlands
🇨🇭
Kantonsspital St. Gallen, Saint Gallen, Switzerland
🇬🇧
The Christie NHS Foundation Trust, Manchester, United Kingdom

and more 37 locations

Study to Assess the Use of Lanreotide Autogel® 120 mg in Patients With Locally Advanced or Metastatic Gastroenteropancreatic Neuroendocrine Tumours (GEP-NETs) in Routine Clinical Practice

Withdrawn

Conditions: Neuroendocrine Tumors

First Posted Date: 2019-03-29

Last Posted Date: 2020-11-05

Lead Sponsor: Ipsen

Registration Number: NCT03895463

Locations: 🇵🇱
Uniwersyteckie Centrum Kliniczne im. Prof. K. Gibińskiego Śląskiego Uniwersytetu Medycznego w Katowicach, Katowice, Poland
🇵🇱
Uniwersyteckie Centrum Kliniczne, Gdańsk, Poland
🇵🇱
Samodzielny Publiczny Szpital Kliniczny Nr 1 Pomorskiego Uniwersytetu Medycznego im. prof. Tadeusza Sokołowskiego, Szczecin, Poland

and more 8 locations

Dose Escalation and Dose Expansion Study of IPN60090 in Patients With Advanced Solid Tumours

Phase 1

Terminated

Conditions: Solid Tumor

Interventions: Drug: IPN60090
Drug: IPN60090 single administration
Drug: pembrolizumab
Drug: paclitaxel

First Posted Date: 2019-03-28

Last Posted Date: 2022-09-13

Lead Sponsor: Ipsen

Target Recruit Count: 22

Registration Number: NCT03894540

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

Validation of Patient Reported Outcome Measures for Use in Hallux Valgus

Completed

Conditions: Hallux Valgus

First Posted Date: 2019-02-20

Last Posted Date: 2020-01-27

Lead Sponsor: Ipsen

Target Recruit Count: 21

Registration Number: NCT03846687

Locations: 🇺🇸
Futuro Clinical Trials, LLC, McAllen, Texas, United States
🇺🇸
Ankle and Foot Care Centers, Youngstown, Ohio, United States
🇺🇸
University Foot and Ankle Institute, Santa Monica, California, United States

Post-marketing Surveillance on the Safety of CabometyxTM in Korean Patients

Completed

Conditions: Hepatocellular Carcinoma
Differentiated Thyroid Carcinoma
Renal Cell Carcinoma

First Posted Date: 2018-12-14

Last Posted Date: 2024-05-29

Lead Sponsor: Ipsen

Target Recruit Count: 347

Registration Number: NCT03776123

Locations: 🇰🇷
Asan Medical Center (Site B), Seoul, Korea, Republic of
🇰🇷
Kyungpook National University Chilgok Hospital, Daegu, Korea, Republic of
🇰🇷
Kosin University Gospel Hospital (Site B), Pusan, Korea, Republic of

and more 44 locations

Evaluate the Safety, Tolerability, Biodistribution and Anti Tumour Activity of 177LU-OPS201 With Companion Imaging 68Ga-OPS202 PET/CT in Previously Treated Subjects With Locally Advanced or Metastatic Cancers Expressing Somatostatin Receptor 2 (SSTR2)

Phase 1

Terminated

Conditions: Small Cell Lung Cancer and Breast Cancer

Interventions: Drug: Satoreotide tetraxetan
Drug: Satoreotide trizoxetan

First Posted Date: 2018-12-12

Last Posted Date: 2022-09-13

Lead Sponsor: Ipsen

Target Recruit Count: 9

Registration Number: NCT03773133

Locations: 🇫🇷
CHU de Marseille - Hôpital la Timone, Marseille, France
🇩🇪
Universitaetsklinikum Essen, Essen, Germany
🇨🇭
University Hospital Basel, Basel, Switzerland

and more 5 locations

Validation of Patient Reported Outcome Measures for Use in Vulvodynia

Completed

Conditions: Vulvodynia

First Posted Date: 2018-12-10

Last Posted Date: 2019-10-28

Lead Sponsor: Ipsen

Target Recruit Count: 20

Registration Number: NCT03770169

Locations: 🇺🇸
San Diego Sexual Medicine, San Diego, California, United States
🇺🇸
Center for Vulvovaginal Disorders, Washington, District of Columbia, United States
🇺🇸
Omaha OB-GYN Associates, PC, Omaha, Nebraska, United States

and more 1 locations

Cabozantinib Real-life Use for Advanced Renal Cell Carcinoma in France: a Retrospective Descriptive Non-interventional Study of 2 Cohorts.

Completed

Conditions: Renal Cell Carcinoma

First Posted Date: 2018-11-16

Last Posted Date: 2019-07-26

Lead Sponsor: Ipsen

Target Recruit Count: 450

Registration Number: NCT03744585

Locations: 🇫🇷
Ipsen Central Contact, Paris, France

Pharmaco-Economic Study of Treatment Options in Patients With Advanced RCC

Completed

Conditions: Renal Cell Carcinoma Metastatic
Renal Cell Carcinoma

First Posted Date: 2018-10-09

Last Posted Date: 2019-08-28

Lead Sponsor: Ipsen

Target Recruit Count: 28

Registration Number: NCT03699579

Locations: 🇨🇳
Taipei Veterans General Hospital, Taipei, Taiwan
🇨🇳
National Taiwan University Hospital, Taipei, Taiwan

Define the Optimal Uptake Time of 68Ga-OPS202 When Used as a PET (Positron Emission Tomography) Imaging Agent in Subjects With Newly Diagnosed Breast Cancer

Phase 2

Terminated

Conditions: Breast Cancer

Interventions: Drug: Satoreotide trizoxetan

First Posted Date: 2018-10-05

Last Posted Date: 2020-09-07

Lead Sponsor: Ipsen

Target Recruit Count: 4

Registration Number: NCT03697551

Locations: 🇦🇹
Medical University Innsbruck, Innsbruck, Austria

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy